CNTB
Connect Biopharma Holdings Limited2.3600
+0.0600+2.61%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
131.93MP/E (TTM)
-Basic EPS (TTM)
-0.89Dividend Yield
0%Recent Filings
8-K
Board director resigns
Connect Biopharma's board lost Kan Chen, Ph.D., Qiming Venture Partners partner, on December 17, 2025, effective immediately from the Board and Nominating Committee. No disagreements over operations or policies. His exit follows the company's U.S.-centric pivot, including stateside management and drug work in U.S./Europe. Smooth transition ahead.
8-K
Q3 loss widens on trials
Connect Biopharma reported Q3 2025 net loss of $17.2M, up from $12.9M last year, driven by higher R&D costs from initiating Phase 2 Seabreeze STAT studies for rademikibart in acute asthma and COPD exacerbations; topline data expected 1H26. Simcere's NDA for rademikibart in atopic dermatitis gained NMPA acceptance. Cash at $54.8M funds operations into 2027. ADR program terminated.
10-Q
Q3 FY2025 results
Connect Biopharma posted a Q3 net loss of $17.2M, up from $12.9M y/y, with diluted EPS slipping to $(0.31) from $(0.23) on 55.7M shares—anti-dilutive options excluded. R&D expenses climbed 23% y/y to $11.1M on rademikibart Phase 2 trials in asthma/COPD exacerbations, while collaboration revenue from Simcere dwindled to $16K from $1.2M. Cash burned fast at $40.0M YTD (derived), leaving $54.8M in cash and equivalents at quarter-end September 30, 2025, funding at least a year. Cash is runway enough. AI upends drug discovery rivals.
8-K
Insider share purchases disclosed
Connect Biopharma's CEO Barry Quart snapped up 224,034 shares between September 2024 and September 2025, while President David Szekeres grabbed 215,739 shares from November 2024 to September 2025. These insider buys, compliant with company policy, signal strong leadership confidence amid biotech volatility. Purchases totaled nearly 440,000 shares. Yet, the filing offers no further strategic details.
10-Q
Q2 FY2025 results
Connect Biopharma posted a Q2 net loss of $12.9 million, or $0.23 per diluted share, swinging from $14.8 million net income last year, driven by a 99.8% drop in license revenue to $48,000 from $24.1 million while research and development expenses climbed 64.2% year-over-year to $8.8 million amid rademikibart Phase 2 trials in asthma and COPD. Operating loss widened to $13.4 million from $10.5 million in expenses, with the net figure reflecting minimal other income of $0.6 million versus $1.2 million prior. Cash burned $22.6 million in operations for the half, leaving $71.8 million in cash and equivalents plus short-term investments at quarter-end, funding needs for at least a year. Simcere's July NDA filing for rademikibart in atopic dermatitis China unlocks up to $110 million in milestones and low double-digit royalties. Cash runway holds firm. Yet clinical trial delays pose risks.
IPO
Employees
Sector
Industry
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
CTNM
Contineum Therapeutics, Inc.
11.55-0.03
CUE
Cue Biopharma, Inc.
0.41-0.05
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
QTTB
Q32 Bio Inc.
2.88-0.17
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
UPB
Upstream Bio, Inc.
29.32+2.12
XBIT
XBiotech Inc.
2.45-0.08